MAX-40279 hemiadipate free base

MAX-40279 is a dual and potent inhibitor of FLT3 kinase.

For research use only. Not for human or veterinary use.

Target FLT3 FGFR

Research area Inflammation/Immunology Cancer

Purity >98% Stock Inquire

Data Sheet SDS COA

MAX-40279 hemiadipate structure

CAS No.: 2388506-44-1

Download structure (.mol)

Pack sizes & pricing

Size	Price	SKU	Stock
100 mg	USD 1,050.00	BP-02230-100mg	In stock	Get quote
250 mg	USD 1,600.00	BP-02230-250mg	In stock	Get quote
500 mg	USD 2,200.00	BP-02230-500mg	In stock	Get quote
1 g	USD 3,200.00	BP-02230-1g	In stock	Get quote
5 g	Inquire	BP-02230-5g	In stock	Inquire
10 g	Inquire	BP-02230-10g	In stock	Inquire

Need another size or custom synthesis? Request a quote.

Description

MAX-40279 is a dual and potent inhibitor of FLT3 kinase and FGFR kinase. MAX-40279 has the potential for the research of acute myelogenous leukemia (AML).

Biological activity

In Vitro MAX-40279 (0.5-1 μM, 48 h) hemiadipate impedes EndMT by inhibiting NDRG1 phosphorylation at Ser-330 in HUVECs, MAECs, and MPLECs. In Vivo MAX-40279 (12 mg/kg, p,o., once daily for 7 days) hemiadipate is effective in 43% of patient tumor samples in mouse Mini-PDX assay. MAX-40279 (12 mg/kg, p,o., twice daily for 21-28 days) hemiadipate significantly inhibited tumor growth in MV4-11 and KG-1 cells induced mice xenograft models. MAX-40279 (7-15 mg/kg, p.o., twice daily for 2-3 weeks) hemiadipate significantly enhances the anti-PD-1 effect in mice breast cancer model. MAX-40279 (p.o., single dose) hemiadipate has much higher drug concentration in bone marrow than in plasma in SD rats

Identifiers

SMILES: O=C(O)CCCCC(O)=O.FC1=CC(OC)=C(C2=C(C)SC3=C2N=C(NC4=CN(C5CCNCC5)N=C4)N=C3)C=C1
InChIKey: CKQKESWOXOJTTB-UHFFFAOYSA-N

Specifications

MW (average): 584.6620
Formula: C₂₈H₃₃FN₆O₅S
CAS No.: 2388506-44-1
Physical state: Solid
Color: Off-white to light yellow
Shipping: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage: Powder -20°C, sealed storage, away from moisture; In solvent -20℃ 1 month;

Solubility

Soluble in DMSO 25 mg/mL DMF 10 mg/mL

In vitro: DMSO : 25 mg/mL DMF : 10 mg/mL

Documents

References

[1]. Yuguang Wang, et al. Novel Therapeutic Methods. Patent WO2021180032A1.

[2]. Yuguang Wang, et al. Preclinical Evaluation of MAX-40279, a FLT3/FGFR Dual Kinase Inhibitor for Treatment of Acute Myeloid Leukemia, Blood, Volume 132, Supplement 1, 2018.

[3]. Xue Z, et al. PIM1 instigates endothelial-to-mesenchymal transition to aggravate atherosclerosis. Theranostics. 2025 Jan 1;15(2):745-765.

Same target

Search FLT3

Same research area

Search Inflammation/Immunology